Merz unveils 'Make Your Mark' campaign
Though the drug has been used abroad since 2005, Xeomin was approved in the US in 2010 for the treatment of adults with cervical dystonia to decrease the severity of abnormal head position and neck pain, and to treat abnormal spasms of the eyelids in adults who have had prior treatment with Botox. Administered as an injectible, Xeomin works to decrease muscle activity, which allows muscles to function more normally for patients diagnosed with either of these conditions.
The web-based campaign was developed by New York agency Medical Dynamics (the public relations AOR), in close partnership with Merz Pharmaceuticals, according to the company's director of marketing, Robert Yanez. This campaign will continue into 2012 and is one of “several initiatives designed to raise awareness of cervical dystonia and blepharospasm and encourage patient dialogue” by Merz Pharmaceuticals, says Yanez.
On the overall objective of the campaign, Yanez explains: “With the help of patient advocates, ‘Make Your Mark' celebrates the inspirational stories of people living with blepharospasm or cervical dystonia, also known as spasmodic torticollis, and aims to raise awareness of these often debilitating conditions.”